Revisiting Clinical Endpoints for the Next Generation of Immuno-Oncology
Tue, Mar 16
|
05:00 PM - 05:30 PM
Track 1
Session details:
As immuno-oncology evolves beyond first-generation PD-1 therapies, are the endpoints that defined the field still the right measures of clinical benefit? This panel will examine how endpoint selection should evolve alongside new therapeutic mechanisms, trial designs, and regulatory expectations.
- Has the role of progression-free survival (PFS) changed in the era of next-generation IO and IO-versus-IO trials?
- When should overall survival (OS), progression-free survival (PFS), or objective response rate (ORR) serve as the primary endpoint?
- How should immune-related response criteria evolve to better capture the unique biology of immunotherapies?
- How can sponsors align endpoint selection with scientific, clinical, and regulatory expectations for emerging IO therapies?
